Catalyst Event
Astrazeneca PLC (AZN) · Other
From KEDI U.S. Medical AI Index (KUSMAI)
6/1/2026, 12:00:00 AM
Announced that the CARES Phase III clinical program for anselamimab, a treatment for light chain amyloidosis, did not meet its primary endpoint in the overall patient population. High importance estimated due to the failure of a late-stage clinical trial.
Korean Translation
경쇄 아밀로이드증 치료제인 안셀라미맙(anselamimab)의 CARES 3상 임상 프로그램이 전체 환자군에서 1차 평가변수를 충족하지 못했다고 발표함. 후기 임상 시험 실패로 인해 높은 중요도로 평가함.
Related Recent Events
Alphabet Inc (GOOGL) · Earnings Release
Alphabet Q2 2026 earnings release scheduled for July 22, 2026, with analysts forecasting EPS of approximately $2.85-$2.87 forecasted.
7/22/2026, 12:00:00 AM
Alphabet Inc (GOOGL) · Other
Alphabet held its 2026 Annual Meeting of Shareholders on June 5, 2026. Proposals included an increase to the 2021 Stock Plan share reserve.
6/5/2026, 12:00:00 AM
Hims & Hers Health Inc (HIMS) · Other
Hims & Hers appointed Dr. Anant Vinjamoori as its new Chief Medical Officer on 2026-06-04, which resulted in a 7.23% stock price increase.
6/4/2026, 12:00:00 AM
Natera Inc (NTRA) · Other
Announced a strategic collaboration with CytoDyn to use its ctDNA platform to support CytoDyn's metastatic colorectal cancer development program.
6/4/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
Announced on 2026-06-03 plans to halve its €2.3 billion investment in a new German plant; medium impact estimated due to regulatory headwinds and reduced growth capacity, expected.
6/3/2026, 12:00:00 AM
Alphabet Inc (GOOGL) · Other
The UK's Competition & Markets Authority (CMA) announced on June 3, 2026, new conduct requirements for Google's AI-powered search, giving publishers more control over their content.
6/3/2026, 12:00:00 AM